195 related articles for article (PubMed ID: 16404704)
21. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model.
Walenga JM; Bakhos M; Messmore HL; Koza M; Wallock M; Orfei E; Fareed J; Pifarre R
Blood Coagul Fibrinolysis; 1991 Feb; 2(1):105-11. PubMed ID: 1772977
[TBL] [Abstract][Full Text] [Related]
22. A quick assay for monitoring recombinant hirudin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II : adaptation of the ecarin clotting time to the act II device.
Koster A; Loebe M; Hansen R; Bauer M; Mertzlufft F; Kuppe H; Hetzer R
J Thorac Cardiovasc Surg; 2000 Jun; 119(6):1278-83. PubMed ID: 10838548
[TBL] [Abstract][Full Text] [Related]
23. Vasoflux, a new anticoagulant with a novel mechanism of action.
Weitz JI; Young E; Johnston M; Stafford AR; Fredenburgh JC; Hirsh J
Circulation; 1999 Feb; 99(5):682-9. PubMed ID: 9950667
[TBL] [Abstract][Full Text] [Related]
24. Different anticoagulants and platelet reactivity in cardiac surgical patients.
John LC; Rees GM; Kovacs IB
Ann Thorac Surg; 1993 Oct; 56(4):899-902. PubMed ID: 8215666
[TBL] [Abstract][Full Text] [Related]
25. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass.
Dietrich W; Spannagl M; Schramm W; Vogt W; Barankay A; Richter JA
J Thorac Cardiovasc Surg; 1991 Oct; 102(4):505-14. PubMed ID: 1833592
[TBL] [Abstract][Full Text] [Related]
26. The effect of antithrombin III-independent thrombin inhibitors and heparin on fibrin accretion onto fibrin-coated polyethylene.
Rubens FD; Weitz JI; Brash JL; Kinlough-Rathbone RL
Thromb Haemost; 1993 Feb; 69(2):130-4. PubMed ID: 8456425
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the inhibition by heparin and hirudin of coagulation activation during r-tPA-induced thrombolysis.
Mirshahi M; Soria J; Soria C; Faivre R; Lu H; Courtney M; Roitsch C; Tripier D; Caen JP
Blood; 1989 Aug; 74(3):1025-30. PubMed ID: 2502207
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Multiplate platelet aggregometry using citrate, heparin or hirudin in Rhesus macaques.
Dugan G; O'Donnell L; Hanbury DB; Cline JM; Caudell DL
Platelets; 2015; 26(8):730-5. PubMed ID: 25549285
[TBL] [Abstract][Full Text] [Related]
29. Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia.
Jabr K; Johnson JH; McDonald MH; Walsh DL; Martin WD; Johnson AC; Pickett JM; Shantha-Martin U
J Extra Corpor Technol; 2004 Jun; 36(2):174-7. PubMed ID: 15334761
[TBL] [Abstract][Full Text] [Related]
30. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model.
Walenga JM; Bakhos M; Messmore HL; Fareed J; Pifarre R
Ann Thorac Surg; 1991 Feb; 51(2):271-7. PubMed ID: 1989543
[TBL] [Abstract][Full Text] [Related]
31. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin.
Wallén NH; Ladjevardi M; Albert J; Bröijersén A
Thromb Res; 1997 Jul; 87(1):151-7. PubMed ID: 9253810
[TBL] [Abstract][Full Text] [Related]
32. Antithrombin III during cardiac surgery: effect on response of activated clotting time to heparin and relationship to markers of hemostatic activation.
Despotis GJ; Levine V; Joist JH; Joiner-Maier D; Spitznagel E
Anesth Analg; 1997 Sep; 85(3):498-506. PubMed ID: 9296400
[TBL] [Abstract][Full Text] [Related]
33. Activation of factor V during intrinsic and extrinsic coagulation. Inhibition by heparin, hirudin and D-Phe-Pro-Arg-Ch2Cl.
Yang XJ; Blajchman MA; Craven S; Smith LM; Anvari N; Ofosu FA
Biochem J; 1990 Dec; 272(2):399-406. PubMed ID: 2268268
[TBL] [Abstract][Full Text] [Related]
34. Quantitative determination of hirudin in blood and body fluids.
Nowak G; Bucha E
Semin Thromb Hemost; 1996; 22(2):197-202. PubMed ID: 8807717
[TBL] [Abstract][Full Text] [Related]
35. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban.
Koster A; Kukucka M; Bach F; Meyer O; Fischer T; Mertzlufft F; Loebe M; Hetzer R; Kuppe H
Anesthesiology; 2001 Feb; 94(2):245-51. PubMed ID: 11176088
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of platelet aggregometry in dogs using the Multiplate platelet analyzer: impact of anticoagulant choice and assay duration.
Marschner CB; Kristensen AT; Spodsberg EH; Wiinberg B
J Vet Emerg Crit Care (San Antonio); 2012 Feb; 22(1):107-15. PubMed ID: 23016746
[TBL] [Abstract][Full Text] [Related]
37. The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation.
Korn RL; Fisher CA; Livingston ER; Stenach N; Fishman SJ; Jeevanadam V; Addonizio VP
J Thorac Cardiovasc Surg; 1996 May; 111(5):1073-84. PubMed ID: 8622305
[TBL] [Abstract][Full Text] [Related]
38. Anticoagulant actions of tissue factor pathway inhibitor on tissue-factor-dependent plasma coagulation.
Ofosu FA
Semin Thromb Hemost; 1995; 21(2):240-4. PubMed ID: 7660146
[TBL] [Abstract][Full Text] [Related]
39. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass--assessment of the whole blood ecarin clotting time.
Pötzsch B; Madlener K; Seelig C; Riess CF; Greinacher A; Müller-Berghaus G
Thromb Haemost; 1997 May; 77(5):920-5. PubMed ID: 9184403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
